Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been assigned an average rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $41.8333.

A number of analysts recently issued reports on the stock. Canaccord Genuity Group raised their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Needham & Company LLC increased their target price on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Wedbush raised their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $32.83 on Friday. Stoke Therapeutics has a 1 year low of $11.66 and a 1 year high of $40.22. The firm has a market cap of $2.04 billion, a PE ratio of -11.68 and a beta of 1.17. The stock has a fifty day moving average price of $31.06 and a 200-day moving average price of $32.36.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. The company had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. As a group, equities analysts anticipate that Stoke Therapeutics will post -3.22 EPS for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 1,457 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the transaction, the general counsel owned 18,086 shares in the company, valued at approximately $541,675.70. This represents a 7.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of Stoke Therapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $30.58, for a total value of $54,891.10. Following the completion of the sale, the insider directly owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. This trade represents a 4.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors have recently added to or reduced their stakes in STOK. Kestra Advisory Services LLC purchased a new stake in Stoke Therapeutics in the 4th quarter worth approximately $26,000. KBC Group NV purchased a new position in shares of Stoke Therapeutics during the 1st quarter valued at $36,000. Harbour Investments Inc. increased its holdings in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in shares of Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.